Medhavi Jogi, MD
Endocrinology, Diabetes & Metabolism · Bellaire, TXNPI 1568484657
Payments from drug & device makers
Across 34 payments — averaging $85.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$2K
- Dexcom, Inc.$235
- Johnson & Johnson$144
- Abbott$40
- Bayer$20
- Amgen$14
- plus $12 from 1 others
What the payments were for
- Speaking & faculty fees$2,45084%
- Food & beverage$41814%
- Education$472%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 9 | $2,450 |
| Dexcom, Inc. | 19 | $235 |
| Johnson & Johnson | 1 | $144 |
| Abbott | 2 | $40 |
| Bayer | 1 | $20 |
| Amgen | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$1,350
- t-slim insulin pump$1,100
- Tremfya$144
How this compares
$2,915 in reported general payments places this provider in the 45th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 191 | $281,139 |
| MounjaroTirzepatide | 90 | $144,720 |
| Humalog Kwikpen U-200Insulin Lispro | 18 | $71,187 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 44 | $64,228 |
| JardianceEmpagliflozin | 44 | $63,460 |
| JanuviaSitagliptin Phosphate | 34 | $49,687 |
| RybelsusSemaglutide | 19 | $32,922 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $32,614 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $32,357 |
| Humalog Kwikpen U-100Insulin Lispro | 65 | $29,740 |
| TrulicityDulaglutide | 17 | $28,054 |
| FarxigaDapagliflozin Propanediol | 22 | $27,501 |
| Novolog FlexpenInsulin Aspart | 69 | $26,619 |
| SynthroidLevothyroxine Sodium | 254 | $25,764 |
| Tresiba Flextouch U-100Insulin Degludec | 43 | $25,269 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Bellaire
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.